USA flag logo/image

An Official Website of the United States Government

Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device

Award Information

Agency:
Department of Defense
Branch:
Office for Chemical and Biological Defense
Award ID:
96626
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
C101-102-0011
Solicitation Year:
N/A
Solicitation Topic Code:
CBD 10-102
Solicitation Number:
N/A
Small Business Information
Physical Optics Corporation
Applied Technologies Division 1845 West 205th Street Torrance, CA 90501-
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device
Agency / Branch: DOD / CBD
Contract: HDTRA1-10-P-0040
Award Amount: $69,990.00
 

Abstract:

To address the CBD need for improved formulations to enhance the ease of use and bioavailability of antisense therapeutics, Physical Optics Corporation (POC) proposes to develop a Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device (MATEN). This proposed system is based on a new dry powder formulation and a novel design of an inhaler that uses in-house developed mature components. POC's innovations in the nanocarrier (NC) construct and in the design of the inhaler, which is capable of delivering a single dose from the MATEN during one deep and slow inspiration, will enhance the bioavailability for antisense therapeutics that is necessary for the prophylaxes and early treatment of warfighters against emerging bio-warfare threats. As a result, this technology offers a formulation that is stable at ambient temperature, minimizes the potential for introduction of immunogenic materials and the bulk and complexity of dispensing, and which directly addresses the requirements of the Transformational Medical Technologies Initiative (TMTI) program. In Phase I, POC will demonstrate the feasibility of the MATEN by demonstrating product stability and establishing enhanced bioavailability in an animal model. In Phase II, POC will optimize candidate formulation for maximum bioavailability and conduct initial pharmacokinetic and pharmacodynamic studies in an animal model.

Principal Investigator:

Gregory Zeltser
Principal Scientist
3103203088
psproposals@poc.com

Business Contact:

Gordon Drew
Chief Financial Officer
3103203088
gedrew@poc.com
Small Business Information at Submission:

Physical Optics Corporation
Photonic Systems Division 20600 Gramercy Place, Bldg. 100 Torrance, CA 90501

EIN/Tax ID: 330118051
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No